US-based biopharmaceutical company Amgen has been granted marketing authorisation by the European Commission (EC) for Mimpara (cinacalcet) to treat secondary hyperparathyroidism (HPT) in children with end-stage renal disease (ESRD).

Secondary HPT is a chronic and severe condition that affects many of the people receiving dialysis.

The condition refers to the excessive secretion of parathyroid hormone (PTH) by the parathyroid glands due to decreased renal function and impaired mineral metabolism.

Amgen received marketing rights for the paediatric formulation (granules in capsule for opening) of Mimpara, the first oral calcimimetic agent approved by the EC, to treat secondary HPT in children aged three and older with ESRD on maintenance dialysis therapy in whom secondary HPT is not adequately controlled with standard-of-care therapy.

"We are pleased with today's approval and the opportunity to provide patients and healthcare providers with an important therapy."

Amgen research and development executive vice-president Dr Sean E. Harper said: “Secondary HPT is a serious and complex condition, and there are currently limited treatment options available for paediatric patients living with this disease.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“We are pleased with today's approval and the opportunity to provide patients and healthcare providers with an important therapy.”

The EC approval is based on the results of the studies conducted by the company as of 2007.

The studies were carried out to evaluate the use of the Amgen treatment in paediatric patients with secondary HPT who have limited treatment options.

With the approval, the company has received a centralised marketing authority in the 28 member countries of the European Union (EU).